Investors Overview

Webcast ImageWebcast
Q2 2015 Xtant Medical Holdings, Inc. Second Quarter 2015 Results Conference Call (Replay)
08/13/15 at 10:00 a.m. ET
Q2 2015 Xtant Medical Holdings, Inc. Second Quarter 2015 Results Conference Call
Thursday, August 13, 2015 10:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile

Bacterin International Holdings, Inc., Belgrade, MT (OTCQX: BONE), a developer of bioactive coatings for medical applications and revolutionary bone graft material, processes and markets innovative, biologic allografts for transplantation. The Company’s biologic scaffolds, OsteoSponge®, OsteoSponge® SC and OsteoWrap®, are made from demineralized bone that is malleable and flexible, which enables more efficient and precise handling. It also markets BacFast® and OsteoLock®, which are used in...
More

Stock Quote
BONE (Common Stock)
(US Dollar)
Price$3.76
Change (%) Stock is Up 0.06 (1.62%)
Volume1,561
Data as of 08/28/15 2:04 p.m. ET
Minimum 20 minute delay
Refresh quote
Stock Chart
Stock chart for: 03NA000000BONE
Recent News
DateTitle 
08/27/15Xtant Medical to Present at the Rodman Renshaw 17th Annual Global Investment Conference
BELGRADE, Mont., Aug. 27, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (OTCQX:BONE), formerly Bacterin International Holdings, Inc., a leader in the development of class-leading regenerative medicine products and medical devices, today announced that its Chief Executive Officer, Dan Goldberger, Chief Financial Officer, John Gandolfo and Executive Vice President and Chief Scientific Officer Dr. David Kirschman will present at the Rodman Renshaw 17th Annual Global Investment Conference, t... 
Printer Friendly Version
08/25/15Xtant Medical Announces FDA Approval of OsteoSelect(R) PLUS
BELGRADE, Mont., Aug. 25, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (OTCQX:BONE), a leader in the development of regenerative medicine products and medical devices, today announced that its wholly owned subsidiary, Bacterin International, Inc., has received FDA 510(k) clearance of OsteoSelect PLUS Demineralized Bone Matrix (DBM) Putty. OsteoSelect PLUS is a next-generation DBM putty, comprised of OsteoSelect Putty with the addition of demineralized cortical chips. Aligned with th... 
Printer Friendly Version
08/12/15Xtant Medical Reports First Half 2015 Financial Results
First Half Xtant(TM) Medical Pro Forma Combined 2015 Highlights: On July 31, 2015, the Company announced the close of its acquisition of X-spine Systems, Inc. Pro forma combined revenue increased 12.6% to $43.4 million from $38.5 million in the first half of 2014 Pro forma gross profit increased 14.3% to $28.0 million compared to $24.5 million in the first half of 2014 Pro forma gross margins improved to 64.6%, an increase from 63.6% in the first half of 2014 Pro ... 
Printer Friendly Version
08/04/15Xtant Medical Holdings, Inc. to Report Second Quarter 2015 Financial Results on August 12, 2015
BELGRADE, Mont., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (BONE), a leader in the development of revolutionary bone graft material, today announced that it will release its financial results for the period ended June 30, 2015, at the close of the financial markets on August 12, 2015. An accompanying conference call will be hosted by Dan Goldberger, Chief Executive Officer, and John Gandolfo, Chief Financial Officer, to discuss the results. The call will be held at 10:00 AM E... 
Printer Friendly Version
More

Upcoming Events
DateTitle
09/09/15 12:05 p.m. ET
Xtant Medical at the Rodman Renshaw 17th Annual Global Investment Conference
More

Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Xtant Medical Holdings, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.